HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Maria Bryszewska Selected Research

poly(propyleneimine)

7/2022Neurotoxicity of poly(propylene imine) glycodendrimers.
1/2020Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL.
1/2014Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: considering their contrary potential as biocompatible entity and drug molecule in cancer.
6/2013The influence of maltotriose-modified poly(propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: dense shell G4 PPI.
5/2010Influence of surface functionality of poly(propylene imine) dendrimers on protease resistance and propagation of the scrapie prion protein.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Maria Bryszewska Research Topics

Disease

25Neoplasms (Cancer)
10/2021 - 07/2007
17Hemolysis
02/2022 - 12/2002
5Neurodegenerative Diseases (Neurodegenerative Disease)
07/2022 - 11/2010
4B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2020 - 06/2013
4Neuroblastoma
01/2020 - 08/2012
3Virus Diseases (Viral Diseases)
04/2022 - 11/2010
3Parkinson Disease (Parkinson's Disease)
11/2021 - 03/2013
3Glioma (Gliomas)
06/2021 - 01/2020
3Breast Neoplasms (Breast Cancer)
08/2020 - 09/2014
3Leukemia
06/2020 - 11/2015
3Alzheimer Disease (Alzheimer's Disease)
01/2020 - 08/2007
3Prion Diseases (Transmissible Spongiform Encephalopathies)
05/2010 - 01/2006
2Wounds and Injuries (Trauma)
10/2021 - 04/2010
2HIV Infections (HIV Infection)
01/2021 - 11/2008
2Prostatic Neoplasms (Prostate Cancer)
12/2020 - 08/2020
2Necrosis
09/2013 - 05/2013
2Stroke (Strokes)
03/2013 - 02/2006
2Body Weight (Weight, Body)
11/2011 - 08/2007
1Brain Neoplasms (Brain Tumor)
07/2022
1Cardiovascular Diseases (Cardiovascular Disease)
04/2022
1Lung Neoplasms (Lung Cancer)
12/2021
1Liver Neoplasms (Liver Cancer)
10/2021
1Drug-Related Side Effects and Adverse Reactions
08/2021
1Glioblastoma (Glioblastoma Multiforme)
06/2021
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
06/2020
1Triple Negative Breast Neoplasms
01/2019
1Acute Promyelocytic Leukemia
01/2019
1Spinal Cord Injuries (Spinal Cord Injury)
11/2015

Drug/Important Bio-Agent (IBA)

43Dendrimers (Dendrons)IBA
07/2022 - 01/2006
13carbosilaneIBA
11/2021 - 01/2018
13Small Interfering RNA (siRNA)IBA
10/2021 - 11/2008
7RutheniumIBA
07/2021 - 01/2018
7Phosphorus (Red Phosphorus)IBA
01/2020 - 11/2010
5poly(propyleneimine)IBA
07/2022 - 05/2010
5Biological ProductsIBA
04/2022 - 01/2008
4Human Serum AlbuminFDA LinkGeneric
12/2020 - 01/2008
4maltotrioseIBA
01/2020 - 11/2012
4ViologensIBA
01/2020 - 03/2013
4Pharmaceutical PreparationsIBA
11/2015 - 08/2010
4Peptides (Polypeptides)IBA
11/2010 - 01/2006
3SynucleinsIBA
11/2021 - 03/2013
3AntigensIBA
01/2021 - 11/2010
3PrionsIBA
01/2020 - 01/2008
3PolymersIBA
07/2019 - 03/2006
3EnzymesIBA
12/2015 - 12/2002
2Nucleic AcidsIBA
12/2021 - 06/2020
2Proteins (Proteins, Gene)FDA Link
09/2021 - 07/2017
2Liposomes (Liposome)IBA
06/2021 - 01/2020
2CopperIBA
08/2020 - 01/2019
2CatalaseIBA
02/2020 - 08/2007
2Hemoglobins (Hemoglobin)IBA
02/2020 - 09/2012
2Anti-Inflammatory Agents (Anti-Inflammatories)IBA
01/2020 - 01/2014
2Drug CarriersIBA
01/2020 - 01/2019
2TanninsIBA
07/2017 - 09/2012
2Photosensitizing Agents (Photosensitizers)IBA
01/2016 - 05/2015
2AntioxidantsIBA
05/2015 - 09/2012
2Nerve Growth Factors (Neurotrophins)IBA
12/2013 - 04/2010
2Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
03/2013 - 02/2006
2BuffersIBA
11/2012 - 03/2012
1Biomarkers (Surrogate Marker)IBA
04/2022
1MicroRNAs (MicroRNA)IBA
04/2022
1poly(ethylenimine sulfide)IBA
02/2022
1OligonucleotidesIBA
12/2021
1Polysaccharides (Glycans)IBA
10/2021
1HydrogelsIBA
10/2021
1Hemostatics (Antihemorrhagics)IBA
10/2021
1carbeneIBA
10/2021
1Ribonucleases (Ribonuclease)IBA
10/2021
1GoldIBA
09/2021
1MianserinIBA
08/2021
1Doxorubicin (Adriamycin)FDA LinkGeneric
07/2021
1Methotrexate (Mexate)FDA LinkGeneric
07/2021
1TRAM 34IBA
06/2021
1Phospholipids (Phosphatides)FDA LinkGeneric
06/2021
1VaccinesIBA
01/2021
1MetalsIBA
12/2020
1dendronIBA
01/2020
1fludarabineIBA
01/2020
1Poly(amidoamine)IBA
01/2020
1PAMAM StarburstIBA
01/2020
1ElementsIBA
01/2019
1Fluorescent Dyes (Fluorescent Probes)IBA
01/2019
1Fluorescein (Funduscein)FDA LinkGeneric
01/2019
1Phosphotransferases (Kinase)IBA
01/2019
1isothiocyanic acidIBA
01/2019
1ChloridesIBA
01/2019
1Fluorescein-5-isothiocyanate (FITC)IBA
01/2019
1NitratesIBA
01/2019
1TNF-Related Apoptosis-Inducing LigandIBA
01/2017
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2017
1NucleosidesIBA
11/2015
1Arabinofuranosylcytosine TriphosphateIBA
11/2015
1nasIBA
11/2015
1pyrimidineIBA
11/2015
1Cytidine Triphosphate (CTP)IBA
11/2015
1Cytarabine (Cytosar-U)FDA LinkGeneric
11/2015
1Ammonium CompoundsIBA
09/2015
1titanium dioxide (Titania)FDA Link
09/2015

Therapy/Procedure

19Therapeutics
12/2021 - 07/2007
1Intravenous Administration
08/2020